Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nigella Sativa for COVID-19 (Nigelle5)
NCT04914767Phase 1Completed
- Sponsor
- Hôpital Universitaire Sahloul
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hôpital Universitaire Sahloul. Primary endpoint: Rate of Death or readmission or requiring oxygen supplementation at 1 month. Started Mar 2021; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04914767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914767.